Global health partnership announces first-, second-line AIDS drugs price reductions in developing world

The Clinton Health Access Initiative, UNITAID, and the U.K.'s Department for International Development (DFID) "said on Tuesday [they] had secured price reductions on key AIDS drugs for HIV-positive patients in poorer countries," Reuters reports. "The price of a first line regimen based on the drug tenofovir would now be less than $159 per patient per year, the partnership said - a reduction of 60 percent from the average price paid in 2008. And a World Health Organization-recommended second-line regimen - needed when patients develop resistance to initial treatment - is now available at less than $410 per year, down sharply from 2008 when poorer countries paid between $800 and $1,200 per patient a year for second-line treatment," the news service reports (Kelland, 4/17).

According to a joint press release, "[t]hese price reductions were made possible through complementary efforts to build demand for new products, which stimulated market competition and led to volume-based discounts, while partnering with suppliers to achieve cost reductions through more efficient manufacturing processes and sourcing of raw materials" (5/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder